Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el uso de tiopurinas en la enfermedad inflamatoria intestinal

Gastroenterología y Hepatología - Tập 41 - Trang 205-221 - 2018
Fernando Bermejo1, Mariam Aguas2,3, María Chaparro3,4, Eugeni Domènech3,5, Ana Echarri6, Esther García-Planella7, Iván Guerra1, Javier P. Gisbert3,4, Antonio López-Sanromán8
1Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, España
2Servicio de Digestivo, Hospital Universitari La Fe, Valencia, España
3Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), España
4Servicios de Digestivo, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, España
5Servicio de Digestivo, Hospital Universitari Germans Trias i Pujol, Badalona, España
6Servicio de Digestivo, Complejo Hospitalario Universitario de Ferrol, Ferrol, España
7Servicio de Digestivo, Hospital Universitari Santa Creu i Sant Pau, Barcelona, España
8Servicio de Digestivo, Hospital Universitario Ramón y Cajal, Madrid, España

Tài liệu tham khảo

Chande, 2013, Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease, Cochrane Database Syst Rev., CD000545 Hazlewood, 2015, Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: A network meta-analysis, Gastroenterology., 148, 344, 10.1053/j.gastro.2014.10.011 Colombel, 2010, Infliximab, azathioprine, or combination therapy for Crohn's disease, N Engl J Med., 362, 1383, 10.1056/NEJMoa0904492 Prefontaine, 2009, Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev., CD000067 Chande, 2015, Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev., CD000067 Gisbert, 2011, Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease, World J Gastroenterol., 17, 3467, 10.3748/wjg.v17.i30.3467 Pearson, 1995, Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis, Ann Intern Med., 123, 132, 10.7326/0003-4819-123-2-199507150-00009 Cosnes, 2013, Early administration of azathioprine vs conventional management of Crohn's disease: A randomized controlled trial, Gastroenterology., 145, 758, 10.1053/j.gastro.2013.04.048 Kariyawasam, 2014, Early use of thiopurines or methotrexate reduces major abdominal and perianal surgery in Crohn's disease, Inflamm Bowel Dis., 20, 1382, 10.1097/MIB.0000000000000119 Gisbert, 2009, Meta-analysis: The efficacy of azathioprine and mercaptopurine in ulcerative colitis, Aliment Pharmacol Ther., 30, 126, 10.1111/j.1365-2036.2009.04023.x Timmer, 2016, Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev., CD000478 Ardizzone, 2006, Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis, Gut., 55, 47, 10.1136/gut.2005.068809 Domenech, 2002, Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis, Aliment Pharmacol Ther., 16, 2061, 10.1046/j.1365-2036.2002.01385.x Campbell, 2005, Ciclosporin use in acute ulcerative colitis: A long-term experience, Eur J Gastroenterol Hepatol., 17, 79, 10.1097/00042737-200501000-00016 Cohen, 1999, Intravenous cyclosporin in ulcerative colitis: A five-year experience, Am J Gastroenterol., 94, 1587, 10.1111/j.1572-0241.1999.01149.x Moskovitz, 2006, Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis, Clin Gastroenterol Hepatol., 4, 760, 10.1016/j.cgh.2006.04.001 Campbell, 2003, Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: The Edinburgh experience of outcome, Dig Liver Dis., 35, 546, 10.1016/S1590-8658(03)00270-6 Actis, 2007, Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: A long-term retrospective cohort study, BMC Gastroenterol., 7, 13, 10.1186/1471-230X-7-13 Rolny, 2002, Longer term outcome of steroid refractory ulcerative colitis treated with intravenous cyclosporine without subsequent oral cyclosporine maintenance therapy, Int J Colorectal Dis., 17, 67, 10.1007/s003840100346 Gomollón, 2013, [Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU], Gastroenterol Hepatol., 36, e1, 10.1016/j.gastrohep.2012.11.001 Laharie, 2012, Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: A parallel, open-label randomised controlled trial, Lancet., 380, 1909, 10.1016/S0140-6736(12)61084-8 Narula, 2016, Systematic review and meta-analysis: Infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids, Am J Gastroenterol., 111, 477, 10.1038/ajg.2016.7 Bojic, 2009, Long-term outcome after admission for acute severe ulcerative colitis in Oxford: The 1992-1993 cohort, Inflamm Bowel Dis., 15, 823, 10.1002/ibd.20843 Canas-Ventura, 2014, Risk of colectomy in patients with ulcerative colitis under thiopurine treatment, J Crohns Colitis., 8, 1287, 10.1016/j.crohns.2014.03.014 Ordás, 2017, Long-term efficacy and safety of cyclosporine in a cohort of steroid-refractory acute severe ulcerative colitis patients from the ENEIDA Registry (1989-2013): A nationwide multicenter study, Am J Gastroenterol., 112, 1709, 10.1038/ajg.2017.180 Domènech, 2017, Gastroenterol Hepatol., 40, 472, 10.1016/j.gastrohep.2017.05.005 Peyrin-Biroulet, 2009, Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: A meta-analysis, Am J Gastroenterol., 104, 2089, 10.1038/ajg.2009.301 Mañosa, 2013, Addition of metronidazole to azathioprine for the prevention of postoperative recurrence of Crohn's disease: A randomized, double-blind, placebo-controlled trial, Inflamm Bowel Dis., 19, 1889 D’Haens, 2008, Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: A controlled randomized trial, Gastroenterology., 135, 1123, 10.1053/j.gastro.2008.07.010 López-Sanromán, 2017, Adalimumab vs azathioprine in the prevention of postoperative Crohn's disease recurrence. A GETECCU randomized trial, J Crohns Colitis., 11, 1293, 10.1093/ecco-jcc/jjx051 D’Haens, 1997, Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease, Gastroenterology., 112, 1475, 10.1016/S0016-5085(97)70027-1 Camus, 2013, Long-term outcome of patients with Crohn's disease who respond to azathioprine, Clin Gastroenterol Hepatol., 11, 389, 10.1016/j.cgh.2012.10.038 Bourrier, 2013, Is there still a room for azathioprine monotherapy in inflammatory bowel disease?, Curr Drug Targets., 14, 1471, 10.2174/13894501113149990172 Markowitz, 2000, A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease, Gastroenterology., 119, 895, 10.1053/gast.2000.18144 Panés, 2013, Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease, Gastroenterology., 145, 766, 10.1053/j.gastro.2013.06.009 Actis, 2009, Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease, World J Gastroenterol., 15, 1420, 10.3748/wjg.15.1420 Rubin, 2008, Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: A clinical review and update, Inflamm Bowel Dis., 14, 265, 10.1002/ibd.20297 Gordillo, 2015, Thiopurine therapy reduces the incidence of colorectal neoplasia in patients with ulcerative colitis. Data from the ENEIDA Registry, J Crohns Colitis., 9, 1063, 10.1093/ecco-jcc/jjv145 Xin, 2005, Effects of aminosalicylates on thiopurine S-methyltransferase activity: An ex vivo study in patients with inflammatory bowel disease, Aliment Pharmacol Ther., 21, 1105, 10.1111/j.1365-2036.2005.02460.x Hande, 2006, 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine, Inflamm Bowel Dis., 12, 251, 10.1097/01.MIB.0000206544.05661.9f Dewit, 2002, Interaction between azathioprine and aminosalicylates: An in vivo study in patients with Crohn's disease, Aliment Pharmacol Ther., 16, 79, 10.1046/j.1365-2036.2002.01156.x Lowry, 2001, Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide, Gut., 49, 656, 10.1136/gut.49.5.656 Andrews, 2009, Systematic review: Does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?, Aliment Pharmacol Ther., 29, 459, 10.1111/j.1365-2036.2008.03915.x López San Román, 2005, Adherence to treatment in inflammatory bowel disease, Rev Esp Enferm Dig., 97, 249, 10.4321/S1130-01082005000400005 Bermejo, 2010, Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies, Ther Adv Chronic Dis., 1, 107, 10.1177/2040622310374897 Treton, 2009, Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: A high risk of relapse, Clin Gastroenterol Hepatol., 7, 80, 10.1016/j.cgh.2008.08.028 Lemann, 2005, A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine, Gastroenterology., 128, 1812, 10.1053/j.gastro.2005.03.031 Cassinotti, 2009, Maintenance treatment with azathioprine in ulcerative colitis: Outcome and predictive factors after drug withdrawal, Am J Gastroenterol., 104, 2760, 10.1038/ajg.2009.410 Bouguen, 2015, Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: A post hoc analysis from SONIC, Inflamm Bowel Dis., 21, 606, 10.1097/MIB.0000000000000302 Panaccione, 2014, Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis, Gastroenterology., 146, 392, 10.1053/j.gastro.2013.10.052 Rahier, 2009, European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease, J Crohns Colitis., 3, 47, 10.1016/j.crohns.2009.02.010 Wasan, 2010, A practical guide to vaccinating the inflammatory bowel disease patient, Am J Gastroenterol., 105, 1231, 10.1038/ajg.2009.733 Gisbert, 2013, Vaccination strategies in patients with IBD, Nat Rev Gastroenterol Hepatol., 10, 277, 10.1038/nrgastro.2013.28 Loras, 2009, Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: A nationwide, multicenter study, Am J Gastroenterol., 104, 57, 10.1038/ajg.2008.4 Loras, 2010, Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy, Gut., 59, 1340, 10.1136/gut.2010.208413 Gisbert, 2012, Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease, Aliment Pharmacol Ther., 35, 1379, 10.1111/j.1365-2036.2012.05110.x Linton, 2013, Prevalence of Epstein-Barr Virus in a population of patients with inflammatory bowel disease: A prospective cohort study, Aliment Pharmacol Ther., 38, 1248, 10.1111/apt.12503 Kopylov, 2012, Prior varicella zoster virus exposure in IBD patients treated by anti-TNFs and other immunomodulators: Implications for serological testing and vaccination guidelines, Aliment Pharmacol Ther., 36, 145, 10.1111/j.1365-2036.2012.05150.x Esposito S, Principi N. Herpes zoster prevention: A difficult problem to solve. Vaccine. 2017 Aug 4. pii: S0264-410X(17)31035-6. doi: 10.1016. Magro, 2013, Epstein-Barr virus in inflammatory bowel disease-correlation with different therapeutic regimens, Inflamm Bowel Dis., 19, 1710, 10.1097/MIB.0b013e318281f31c Hradsky, 2015, Seroprevalence of Epstein-Barr virus, cytomegalovirus, and polyomaviruses in children with inflammatory bowel disease, Dig Dis Sci., 60, 3399, 10.1007/s10620-015-3764-z Fries, 2013, Systematic review: Macrophage activation syndrome in inflammatory bowel disease, Aliment Pharmacol Ther., 37, 1033, 10.1111/apt.12305 Lennard, 1999, Therapeutic drug monitoring of antimetabolic cytotoxic drugs, Br J Clin Pharmacol., 47, 131, 10.1046/j.1365-2125.1999.00884.x Dubinsky, 2000, Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease, Gastroenterology., 118, 705, 10.1016/S0016-5085(00)70140-5 Weinshilboum, 1978, Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical properties, Clin Chim Acta., 85, 323, 10.1016/0009-8981(78)90311-X Gisbert, 2007, Thiopurine methyltransferase activity in Spain: A study of 14,545 patients, Dig Dis Sci., 52, 1262, 10.1007/s10620-006-9119-z Jacqz-Aigrain, 1994, Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors, Br J Clin Pharmacol., 38, 1, 10.1111/j.1365-2125.1994.tb04314.x Vesell, 1997, Therapeutic lessons from pharmacogenetics, Ann Intern Med., 126, 653, 10.7326/0003-4819-126-8-199704150-00012 González-Lama, 2011, Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients, Aliment Pharmacol Ther., 34, 544, 10.1111/j.1365-2036.2011.04756.x Yates, 1997, Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance, Ann Intern Med., 126, 608, 10.7326/0003-4819-126-8-199704150-00003 Rossi, 2001, Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects, Eur J Clin Pharmacol., 57, 51, 10.1007/s002280000246 Relling, 1999, Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus, J Natl Cancer Inst., 91, 2001, 10.1093/jnci/91.23.2001 Nielsen, 2001, Review article: The treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine, Aliment Pharmacol Ther., 15, 1699, 10.1046/j.1365-2036.2001.01102.x Sandborn, 2001, Rational dosing of azathioprine and 6-mercaptopurine, Gut., 48, 591, 10.1136/gut.48.5.591 Fong, 2015, Getting the best out of thiopurine therapy: Thiopurine S-methyltransferase and beyond, Biomark Med., 9, 51, 10.2217/bmm.14.97 Dart, 2017, Optimising use of thiopurines in inflammatory bowel disease, Expert Rev Clin Immunol., 13, 877, 10.1080/1744666X.2017.1351298 Shih, 2012, Split-dose administration of thiopurine drugs: A novel and effective strategy for managing preferential 6-MMP metabolism, Aliment Pharmacol Ther., 36, 449, 10.1111/j.1365-2036.2012.05206.x Fraser, 2002, The efficacy of azathioprine for the treatment of inflammatory bowel disease: A 30 year review, Gut., 50, 485, 10.1136/gut.50.4.485 Chaparro, 2013, Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients, Inflamm Bowel Dis., 19, 1404, 10.1097/MIB.0b013e318281f28f Benichou, 1990, Criteria of drug-induced liver disorders. Report of an international consensus meeting, J Hepatol., 11, 272, 10.1016/0168-8278(90)90124-A Bermejo, 2008, Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis, Aliment Pharmacol Ther., 28, 623, 10.1111/j.1365-2036.2008.03746.x Costantino, 2012, Thiopurine treatment in inflammatory bowel disease: Response predictors, safety, and withdrawal in follow-up, J Crohns Colitis., 6, 588, 10.1016/j.crohns.2011.11.007 Gisbert, 2008, Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: A review, Am J Gastroenterol., 103, 1783, 10.1111/j.1572-0241.2008.01848.x Weinshilboum, 1980, Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity, Am J Hum Genet., 32, 651 Gisbert, 2007, Thiopurine-induced liver injury in patients with inflammatory bowel disease: A systematic review, Am J Gastroenterol., 102, 1518, 10.1111/j.1572-0241.2007.01187.x Bastida, 2005, Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease, Aliment Pharmacol Ther., 22, 775, 10.1111/j.1365-2036.2005.02636.x Romagnuolo, 1998, Cholestatic hepatocellular injury with azathioprine: A case report and review of the mechanisms of hepatotoxicity, Can J Gastroenterol., 12, 479, 10.1155/1998/294752 Calabrese, 2011, Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease, J Crohns Colitis., 5, 48, 10.1016/j.crohns.2010.08.007 Seksik, 2011, Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine, Inflamm Bowel Dis., 17, 565, 10.1002/ibd.21330 Kennedy, 2013, A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: An observational study, systematic review and meta-analysis, Aliment Pharmacol Ther., 38, 1255, 10.1111/apt.12511 Seksik, 2009, Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine, Aliment Pharmacol Ther., 29, 1106, 10.1111/j.1365-2036.2009.03973.x Campillo, 2008, ¿Cuál es la mejor pauta de seguimiento en pacientes con enfermedad inflamatoria intestinal en tratamiento con tiopurinas? Comparación entre control trimestral o semestral. Abstract Reunión AEG, Gastroenterol Hepatol., 31, 177 Domènech, 2005, 6-mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine, Scand J Gastroenterol., 40, 52, 10.1080/00365520410009492 Lees, 2008, Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease, Aliment Pharmacol Ther., 27, 220, 10.1111/j.1365-2036.2007.03570.x Hindorf, 2009, Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease, Aliment Pharmacol Ther., 29, 654, 10.1111/j.1365-2036.2008.03925.x Bermejo, 2010, Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease, Aliment Pharmacol Ther., 31, 120, 10.1111/j.1365-2036.2009.04132.x McGovern, 2002, Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity, Gastroenterology., 122, 838, 10.1053/gast.2002.32124 Ansari, 2008, Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease, Aliment Pharmacol Ther., 28, 734, 10.1111/j.1365-2036.2008.03782.x Ansari, 2010, Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease, Aliment Pharmacol Ther., 31, 640, 10.1111/j.1365-2036.2009.04221.x Pavlidis, 2016, Long-term safety and efficacy of low-dose azathioprine and allopurinol cotherapy in inflammatory bowel disease: A large observational study, Inflamm Bowel Dis., 22, 1639, 10.1097/MIB.0000000000000827 Candy, 1995, A controlled double blind study of azathioprine in the management of Crohn's disease, Gut., 37, 674, 10.1136/gut.37.5.674 Connell, 1993, Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience, Gut., 34, 1081, 10.1136/gut.34.8.1081 Algaba, 2015, Incidence, management, and course of cancer in patients with inflammatory bowel disease, J Crohns Colitis., 9, 326, 10.1093/ecco-jcc/jjv032 Annese, 2015, European Evidence-based Consensus: Inflammatory bowel disease and malignancies, J Crohns Colitis., 9, 945, 10.1093/ecco-jcc/jjv141 Ariyaratnam, 2014, Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: A meta-analysis, Am J Gastroenterol., 109, 163, 10.1038/ajg.2013.451 Singh, 2014, Inflammatory bowel disease is associated with an increased risk of melanoma: A systematic review and meta-analysis, Clin Gastroenterol Hepatol., 12, 210, 10.1016/j.cgh.2013.04.033 Beaugerie, 2009, Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study, Lancet., 374, 1617, 10.1016/S0140-6736(09)61302-7 Kotlyar, 2015, Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: A meta-analysis, Clin Gastroenterol Hepatol., 13, 847, 10.1016/j.cgh.2014.05.015 Lopez, 2014, Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease, Clin Gastroenterol Hepatol., 12, 1324, 10.1016/j.cgh.2014.02.026 Bourrier, 2016, Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study, Aliment Pharmacol Ther., 43, 252, 10.1111/apt.13466 Rubin, 2013, Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: A case-control study, Clin Gastroenterol Hepatol., 11, 1601e1, 10.1016/j.cgh.2013.06.023 Magro, 2014, Extra-intestinal malignancies in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (III), J Crohns Colitis., 8, 31, 10.1016/j.crohns.2013.04.006 Chaparro, 2017, Extracolonic cancer in inflammatory bowel disease: Data from the GETECCU Eneida Registry, Am J Gastroenterol., 112, 1135, 10.1038/ajg.2017.96 Rahier, 2014, Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease, J Crohns Colitis., 8, 443, 10.1016/j.crohns.2013.12.013 Axelrad, 2016, Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents, Clin Gastroenterol Hepatol., 14, 58, 10.1016/j.cgh.2015.07.037 Beaugerie, 2014, Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer, Gut., 63, 1416, 10.1136/gutjnl-2013-305763 Mañosa, 2016, Use of immunosuppressants and biological agents in IBD patients with past history of cancer, United European Gastroenterol J., 4, A27 Beaugerie, 2013, Use of immunosuppressants and biologicals in patients with previous cancer, Dig Dis., 31, 254, 10.1159/000353382 Van der Woude, 2015, The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease, J Crohns Colitis., 9, 107, 10.1093/ecco-jcc/jju006 Garrido, 2010, Enfermedad inflamatoria intestinal y gestación, Gastroenterol Hepatol., 33, 517, 10.1016/j.gastrohep.2009.11.006 Gisbert, 2010, Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding, Inflamm Bowel Dis., 16, 881, 10.1002/ibd.21154 Casanova, 2013, Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease, Am J Gastroenterol., 108, 433, 10.1038/ajg.2012.430 Teruel, 2010, Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines, Am J Gastroenterol., 105, 2003, 10.1038/ajg.2010.138 Valer, 2017, Evaluation of the quality of semen and sexual function in men with inflammatory bowel disease, Inflamm Bowel Dis., 23, 1144, 10.1097/MIB.0000000000001081 Dignass, 2010, The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management, J Crohns Colitis., 4, 28, 10.1016/j.crohns.2009.12.002 Lichtenstein, 2006, American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease, Gastroenterology., 130, 935, 10.1053/j.gastro.2006.01.047 Carter, 2004, Guidelines for the management of inflammatory bowel disease in adults, Gut., 53, V1, 10.1136/gut.2004.043372 Benkov, 2013, Role of thiopurine metabolite testing and thiopurine methyltransferase determination in pediatric IBD, J Pediatr Gastroenterol Nutr., 56, 333, 10.1097/MPG.0b013e3182844705 Ruemmele, 2014, Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease, J Crohns Colitis., 8, 1179, 10.1016/j.crohns.2014.04.005 Smith, 2013, The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic, Int J Clin Pract., 67, 161, 10.1111/ijcp.12039 Osterman, 2006, Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: A meta-analysis, Gastroenterology., 130, 1047, 10.1053/j.gastro.2006.01.046 Moreau, 2014, Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: A meta-analysis, Inflamm Bowel Dis., 20, 464, 10.1097/01.MIB.0000439068.71126.00 Irving, 2014, Are we using and monitoring thiopurines and biologics optimally?, Dig Dis., 32, 410, 10.1159/000358147 Chouchana, 2012, Review article: The benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease, Aliment Pharmacol Ther., 35, 15, 10.1111/j.1365-2036.2011.04905.x Louis, 2014, Use of azathioprine in IBD: Modern aspects of an old drug, Gut., 63, 1695, 10.1136/gutjnl-2013-306711 Smith, 2012, Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol, J Crohns Colitis., 6, 905, 10.1016/j.crohns.2012.02.007 Roblin, 2016, Thiopurine metabolism in the era of combotherapy, Inflamm Bowel Dis., 22, 1496, 10.1097/MIB.0000000000000737 Rosen, 2016, The evolving role of thiopurines for inflammatory bowel disease, Inflamm Bowel Dis., 22, 234, 10.1097/MIB.0000000000000583 Roblin, 2017, Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: An open-label, prospective and randomised clinical trial, Aliment Pharmacol Ther., 46, 142, 10.1111/apt.14106 Kariyawasam, 2017, Inflamm Bowel Dis., 23, 1555, 10.1097/MIB.0000000000001183 Nakase, 2017, Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: A subanalysis of the DIAMOND trial, Aliment Pharmacol Ther., 46, 873, 10.1111/apt.14318